Type I interferons in the treatment of pancreatic cancer: Mechanisms of action and role of related Receptors

Annals of Surgery

Volumn 246, Issue 2, 2007, Pages 259-268

  Vitale, Giovanni ^a   Van Eijck, Casper H J ^a   Van Koetsveld Ing, Peter M ^a   Erdmann, Joris I ^a   Speel, Ernst Jan M ^b   Van Der Wansem Ing, Katy ^a   Mooij, Diana M ^a   Colao, Annamaria ^c   Lombardi, Gaetano ^c   Croze, Ed ^d   Lamberts, Steven W J ^a   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA1A INTERFERON; DNA FRAGMENT; RECOMBINANT ALPHA2B INTERFERON;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INCUBATION TIME; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY EFFECT;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE I; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTOR, INTERFERON ALPHA-BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 34547568178     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000261460.07110.f2     Document Type: Article

References (49)

1. Sohn T, Yeo C, Cameron J, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
2. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
3. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-782.
4. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003;185:476-480.
5. Lindner DJ, Borden EC, Kalvakolanu DV. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Clin Cancer Res. 1997;3:931-937.
6. Takaoka A, Taniguchi T. New aspects of IFN-α/β signalling in immunity, oncogenesis and bone metabolism. Cancer Sci. 2003;94:405-411.
7. Mitchell MS. Combination of anticancer drugs and immunotherapy. Cancer Immunol Immunother. 2003;52:686-692.
8. Vitale G, Tagliaferri P, Caraglia M, et al. Slow release lanreotide in combination with interferon-α2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab. 2000;85:983-988.
9. Vitale G, Caraglia M, Ciccarelli A, et al. Current approaches in the therapy of medullary thyroid carcinoma. Cancer. 2001;91:1797-1808.
10. Johns TG, Mackay IR, Callister KA, et al. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst. 1992;84:1185-1190.
11. Xie K, Bielenberg D, Huang S, et al. Abrogation of tumorigenicity and metastasis of murine and human tumor cells by transfection with the murine IFN-beta gene: possible role of nitric oxide. Clin Cancer Res. 1997;3:2283-2294.
12. Giandomenico V, Vaccari G, Fiorucci G, et al. Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-α, interferon-β and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21. Eur Cytokine Netw. 1998;9:619-631.
13. Rosenblum MG, Yung WKA, Kelleher PJ, et al. Growth inhibitory effects of interferon-β but not interferon-α on human glioma cells: correlation of receptor binding 2′,5′-oligoadenylate synthetase and protein kinase activity. J Interferon Res. 1990;10:141-151.
14. Coradini D, Biffi A, Pirronello E, et al. The effect of α-, β- and λ-interferon on the growth of breast cancer cell lines. Anticancer Res. 1994;14:1779-1784.
15. Damdinsuren B, Nagano H, Sakon M, et al. Interferon-β is more potent than interferon-α in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol. 2003;10:1184-1190.
16. Vitale G, de Herder WW, van Koetsveld PM, et al. Interferon-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res. 2006;66:554-562.
17. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-2972.
18. INK4, methylthioadenosine phosphorylase, and the α- and β-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Cancer Res. 1996;56:1083-1090.
19. Hofland LJ, van Koetsveld PM, Lamberts SW. Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201-995. Eur J Cancer. 1990;26:37-44.
20. Ferone D, Pivonello R, van Hagen PM, et al. Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab. 2002;283:E1056-E1066.
21. John WJ, Flett MO. Continuous venous infusion of 5-fluorouracil and interferon-alpha in pancreatic carcinoma. Am J Clin Oncol. 1998;21:147-150.
22. Sparano J, Lipsitz S, Wadler S, et al. Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer: Eastern Cooperative Oncology Group protocol 3292. Am J Clin Oncol. 1996;19:546 -551.
23. Nukui Y, Picozzi VJ, Traverso LW. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2000;179:367-371.
24. Brembeck FH, Schoppmeyer K, Leupold U, et al. A phase II pilot trial of 13-cis retinoic acid and interferon-α in patients with advanced pancreatic carcinoma. Cancer. 1998;83:2317-2323.
25. Sporn JR, Buzaid AC, Slater D, et al. Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin. Am J Clin Oncol. 1997;20:81-83.
26. Bernhard H, Jager-Arand E, Bernhard G, et al. Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial. Br J Cancer. 1995;71:102-105.
27. Wang B, Xiong Q, Shi Q, et al. Intact nitric oxide synthase II gene is required for interferon-β-mediated suppression of growth and metastasis of pancreatic adenocarcinoma. Cancer Res. 2001;61:71-75.
28. Endou M, Mizuno M, Nagata T, et al. Growth inhibition of human pancreatic cancer cells by human interferon-β gene combined with gemcitabine. Int J Mol Med. 2005;15:277-283.
29. Busch M, Wilkowski R, Schaffer M, et al. Combined chemotherapy, radiotherapy, and immunotherapy for pancreatic carcinoma: a case report. Adv Ther. 2000;17:133-139.
30. Recchia F, Sica G, Casucci D, et al. Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. Am J Clin Oncol. 1998;21:275-279.
31. Saidi RF, Williams F, Ng F, et al. Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines. Am J Surg. 2006;191:358-363.
32. Ota H, Nagano H, Doki Y, et al. Expression of type I interferon receptor as a predictor of clinical response to interferon-α therapy of gastrointestinal cancers. Oncol Rep. 2006;16:249-255.
33. Saidi RF, Williams F, Silberberg B, et al. Expression of interferon receptors in pancreatic cancer: identification of a novel prognostic factor. Surgery. 2006;139:743-748.
34. Mogensen KE, Lewerenz M, Reboul J, et al. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res. 1999;19:1069-1098.
35. Deonarain R, Chan DCM, Platanias LC, et al. Interferon-α/β- receptor interactions: a complex story unfolding. Curr Pharm Des. 2002;8:2131-2137.
36. Domanski P, Witte M, Kellum M, et al. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signalling. J Biol Chem. 1995;270:21606-21611.
37. Domanski P, Colamonici OR. The type-I interferon receptor: the long and short of it. Cytokine Growth Factor Rev. 1996;7:143-151.
38. Pestka S. The interferon receptors. Semin Oncol. 1997;24(suppl 9):18-40.
39. Cohen B, Novick D, Barak S, et al. Ligand-induced association of the type I interferon receptor components. Mol Cell Biol. 1995;15:4208-4214.
40. Pfeffer LM, Basu L, Pfeffer SR, et al. The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action. J Biol Chem. 1997;272:11002-11005.
41. Hardy MP, Owczarek CM, Trajanovska S, et al. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood. 2001;97:473-482.
42. McKenna SD, Vergilis K, Arulanandam AR, et al. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice. J Interferon Cytokine Res. 2004;24:119-129.
43. Buchwalder PA, Buclin T, Trinchard I, et al. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res. 2000;20:857-866.
44. Salmon P, Le Cotonnec JY, Galazka A, et al. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res. 1996;16:759-764.
45. Wagner TC, Velichko S, Chesney SK, et al. Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer. 2004;111:32-42.
46. Jaks E, Gavutis M, Uze G, et al. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol. 2006;18 (Epub ahead of print).
47. Klaus W, Gsell B, Labhardt AM, et al. The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution. J Mol Biol. 1997;274:661-675.
48. Karpusas M, Nolte M, Benton CB, et al. The crystal structure of human interferon beta at 2. 2-A resolution. Proc Natl Acad Sci USA. 1997;94:11813-11818.
49. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp Hematol. 1999;27:1583-1592.